BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178

Benzinga Newsdesk www.benzinga.com Positive 92.9%

Neg 0% Neu 0% Pos 92.9%

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.